Sodium chloride 6% 
Ampoule 10ml

Nebulizer soluition

Indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous
secretions
Clean the airway

Hold vial gently twist and pull off top. Invert and squeeze to dispense prescribed volume into the nebulizer cup.

Acetylcysteine 1000mg/10ml

Nebulizer solution

Indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions

Nebulization — Face Mask, Mouthpiece, Tracheostomy:

When nebulized into a face mask, mouthpiece, or tracheostomy, 2 to 20 mL of the 10% solution may be given every 2 to 6 hours; the recommended dose for most patients is 6 to 10 mL of the 10% solution three to four times a day.

Nebulization — Tent, Croupette:

In special circumstances it may be necessary to nebulize into a tent or Croupette, and this method of use must be individualized to take into account the available equipment and the patient’s particular needs. This form of administration requires very large volumes of the solution, occasionally as much as 300 mL during a single treatment period.

If a tent or Croupette must be used, the recommended dose is the volume of acetylcysteine that will maintain a very heavy mist in the tent or Croupette for the desired period. Administration for intermittent or continuous prolonged periods, including overnight, may be desirable.

Direct Instillation:

When used by direct instillation, 1 to 2 mL of a 10% solution may be given as often as every hour.

When used for the routine nursing care of patients with tracheostomy, 1 to 2 mL of a 10% solution may be given every 1 to 4 hours by instillation into the tracheostomy.

Acetylcysteine may be introduced directly into a particular segment of the bronchopulmonary tree by inserting (under local anesthesia and direct vision) a small plastic catheter into the trachea.

Acetylcysteine may also be given through a percutaneous intratracheal catheter. Two to 4 mL of the 10% solution every 1 to 4 hours may then be given by a syringe attached to the catheter.

Diagnostic Bronchograms:

For diagnostic bronchial studies, 2 or 3 administrations of  2 to 4 mL of the 10% solution should be given by nebulization or by instillation intratracheally, prior to the procedure.

If only a portion of the solution in a vial is used, store the remainder in a refrigerator and use for inhalation only within 96 hours.

Salbutamol  (as salbutamol sulfate) 2.5mg/2.5ml

Solution for Nebuliser

Indicated for use in the routine management of chronic bronchospasm unresponsive to conventional therapy and the treatment of acute severe asthma

Zensalbu Nebules 2.5 are for inhalation use only, to be breathed in through the mouth, under the direction of a physician, using a suitable nebuliser.

The solution should not be injected or swallowed.

Adults (including the elderly): 2.5 mg to 5 mg salbutamol up to four times a day. Up to 40 mg per day can be given under strict medical supervision in hospital.

Paediatric Population

Children aged 12 years and over: Dose as per adult population.

Children aged 4-11 years: 2.5 mg to 5 mg up to four times a day.

Other pharmaceutical forms may be more appropriate for administration in children under 4 years old.

Infants under 18 months old: Clinical efficacy of nebulised salbutamol in infants under 18 months is uncertain. As transient hypoxia may occur supplemental oxygen therapy should be considered.

Zensalbu Nebules 2.5 are intended to be used undiluted. However, if prolonged delivery time (more than 10 minutes) is required, the solution may be diluted with sterile normal saline.

Budesonide 0.5mg/2ml

Nebulizer suspension

Treatment of asthma and as prophylactic therapy

Posology

Asthma

The dose should be given twice daily.

Administration once daily may be considered in cases of mild to moderate stable asthma.

Initial dosage:

The initial dose should be tailored to the severity of the disease and thereafter should be adjusted on an individual basis. The following doses are recommended but the minimum effective dose should always be sought:

Children aged 6 months and above:

0.25 – 1.0mg daily. For patients in maintenance therapy with oral steroids a higher initial dosage up to 2.0 mg daily should be considered.

Adults (including the elderly) and children/adolescents over 12 years of age:

0.5 - 2 mg daily. In very severe cases the dosage may be increased further.

Maintenance dose:

The maintenance dose should be adjusted to meet the requirements of the individual patient taking account of the severity of the disease and the clinical response of the patient. When the desired clinical effect has been obtained, the maintenance dose should be reduced to the minimum required for control of the symptoms.

Children aged 6 months and above:

0.25 - 1.0mg daily.

Adults (including the elderly) and children/adolescents over 12 years of age:

0.5 - 2.0mg daily. In very severe cases the dose may be further increased.

Administration once daily:

Administration once daily should be considered for children and adults with mild to moderate stable asthma and with a maintenance dose between 0.25 mg and 1 mg budesonide daily. Once-daily administration may be initiated both in patients who are not receiving corticosteroid treatment and in well-controlled patients who are already taking inhaled steroids. The dose may be given in the morning or evening. If a worsening of the asthma occurs, the daily dose should be increased by administering the dose twice daily.

Onset of effect:

An improvement of the asthma following administration of budesonide may occur within 3 days after initiation of therapy. The maximum effect will only be obtained after 2-4 weeks of treatment.

Each 2.5 ml ampoule contains:
Salbutamol (as salbutamol sulfate) 2.5mg
Ipratropium bromide 0.5mg

Solution for Nebuliser

The management of bronchospasm in patients suffering from chronic obstructive pulmonary disease who require regular treatment with both ipratropium and salbutamol.

The recommended dose is: 1 single dose unit three or four times daily.

Instructions for use

The unit dose vials are intended only for inhalation with suitable nebulising devices and should not be taken orally or administered parenterally.

The content of the unit dose vials does not need to be diluted for nebulization.

Prepare the nebuliser for filling, according to the instruction provided by the manufacturer or doctor.
Open the pouch foil and tear one unit dose vial from the strip
Open the unit dose vial by firmly twisting the top
Squeeze the content of the unit dose vial into the nebuliser reservoir
Assemble the nebuliser and use as directed
After use throw away any solution left in the reservoir and clean the nebuliser, following the manufacturer's instructions
Since the single dose units contain no preservatives, it is important that the contents are used immediately after opening and that a fresh vial is used for each administration to avoid microbial contamination. Partly used, open or damaged single dose units should be discarded.

It is strongly recommended not to mix ZENCOMBI with other drugs in the same nebuliser.

Sodium chloride 3%

Solution for Nebuliser

Indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions.

Help clean the airway.

How can use:

1. Hold vial and gently twist the cap

2. Pull off top. Invert and squeeze to dispense prescribed volume into the nebulizer cup.

3. Clean nebulizer after using

Salbutamol (as salbutamol sulfate) 5mg/2.5ml

Nebulizer solution

Indicated for use in the routine management of chronic bronchospasm unresponsive to conventional therapy and the treatment of acute severe asthma

Zensalbu nebules 5.0 are for inhalation use only, to be breathed in through the mouth, under the direction of a physician, using a suitable nebuliser.

The solution should not be injected or swallowed.

Adults (including the elderly): 2.5 mg to 5 mg salbutamol up to four times a day. Up to 40 mg per day can be given under strict medical supervision in hospital.

Paediatric Population

Children aged 12 years and over: Dose as per adult population.

Children aged 4-11 years: 2.5 mg to 5 mg up to four times a day.

Other pharmaceutical forms may be more appropriate for administration in children under 4 years old.

Infants under 18 months old: Clinical efficacy of nebulised salbutamol in infants under 18 months is uncertain. As transient hypoxia may occur supplemental oxygen therapy should be considered.

Zensalbu nebules 5.0 are intended to be used undiluted. However, if prolonged delivery time (more than 10 minutes) is required, the solution may be diluted with sterile normal saline.